Lv41
740 积分 2024-07-08 加入
Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting
1个月前
已完结
Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas
2个月前
已完结
BV-CHP in Previously Untreated Patients with CD30-Positive Adult T-Cell Leukemia-Lymphoma: A Multicenter Real-World Retrospective Study
2个月前
已关闭
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study
10个月前
已完结
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes
10个月前
已完结
Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Mature T-cell, NK-cell and Stroma-Derived Neoplasms of Lymphoid Tissues
11个月前
已完结
A practical approach to the modern diagnosis and classification of T-and NK-cell lymphomas
11个月前
已完结
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study
11个月前
已完结
Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment
11个月前
已完结
皖公网安备34019202002308
